Clarus Lifesciences Ii, L.p. - Net Worth and Insider Trading
Clarus Lifesciences Ii, L.p. Net Worth
The estimated net worth of Clarus Lifesciences Ii, L.p. is at least $130 Million dollars as of 2024-05-11. Clarus Lifesciences Ii, L.p. is the 10% Owner of Achillion Pharmaceuticals Inc and owns about 10,942,471 shares of Achillion Pharmaceuticals Inc (ACHN) stock worth over $74 Million. Clarus Lifesciences Ii, L.p. is the 10% Owner of Aerie Pharmaceuticals Inc and owns about 3,603,603 shares of Aerie Pharmaceuticals Inc (AERI) stock worth over $55 Million. Clarus Lifesciences Ii, L.p. is also the 10% Owner of Astria Therapeutics Inc and owns about 45,875 shares of Astria Therapeutics Inc (ATXS) stock worth over $446,364. Besides these, Clarus Lifesciences Ii, L.p. also holds NanoString Technologies Inc (NSTGQ) . Details can be seen in Clarus Lifesciences Ii, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Clarus Lifesciences Ii, L.p. has not made any transactions after 2019-03-22 and currently still holds the listed stock(s).
Transaction Summary of Clarus Lifesciences Ii, L.p.
Clarus Lifesciences Ii, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Clarus Lifesciences Ii, L.p. owns 7 companies in total, including NanoString Technologies Inc (NSTGQ) , Venus Concept Inc (VERO) , and TetraLogic Pharmaceuticals Corp (TLOG) among others .
Click here to see the complete history of Clarus Lifesciences Ii, L.p.’s form 4 insider trades.
Insider Ownership Summary of Clarus Lifesciences Ii, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| NSTGQ | NanoString Technologies Inc | 2019-03-22 | 10 percent owner |
| VERO | Venus Concept Inc | 2017-10-11 | 10 percent owner |
| TLOG | TetraLogic Pharmaceuticals Corp | 2016-02-08 | 10 percent owner |
 | | 2015-06-30 | 10 percent owner |
| | 2013-09-25 | 10 percent owner |
| | 2014-12-23 | 10 percent owner |
| | 2012-06-04 | 10 percent owner |
Clarus Lifesciences Ii, L.p. Latest Holdings Summary
Clarus Lifesciences Ii, L.p. currently owns a total of 4 stocks. Among these stocks, Clarus Lifesciences Ii, L.p. owns 10,942,471 shares of Achillion Pharmaceuticals Inc (ACHN) as of May 31, 2012, with a value of $74 Million and a weighting of 57.09%. Clarus Lifesciences Ii, L.p. owns 3,603,603 shares of Aerie Pharmaceuticals Inc (AERI) as of December 23, 2014, with a value of $55 Million and a weighting of 42.41%. Clarus Lifesciences Ii, L.p. also owns 45,875 shares of Astria Therapeutics Inc (ATXS) as of June 30, 2015, with a value of $446,364 and a weighting of 0.34%. The other 1 stocks NanoString Technologies Inc (NSTGQ) have a combined weighting of 0.16% among all his current holdings.
Latest Holdings of Clarus Lifesciences Ii, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ACHN | Achillion Pharmaceuticals Inc | 2012-05-31 | 10,942,471 | 6.76 | 73,971,104 |
| AERI | Aerie Pharmaceuticals Inc | 2014-12-23 | 3,603,603 | 15.25 | 54,954,946 |
| ATXS | Astria Therapeutics Inc | 2015-06-30 | 45,875 | 9.73 | 446,364 |
| NSTGQ | NanoString Technologies Inc | 2019-03-22 | 2,036,025 | 0.10 | 201,566 |
Holding Weightings of Clarus Lifesciences Ii, L.p.
Clarus Lifesciences Ii, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Clarus Lifesciences Ii, L.p. has made a total of 0 transactions in Achillion Pharmaceuticals Inc (ACHN) over the past 5 years. The most-recent trade in Achillion Pharmaceuticals Inc is the sale of 1,316,956 shares on May 31, 2012, which brought Clarus Lifesciences Ii, L.p. around $10 Million.
According to the SEC Form 4 filings, Clarus Lifesciences Ii, L.p. has made a total of 0 transactions in Aerie Pharmaceuticals Inc (AERI) over the past 5 years. The most-recent trade in Aerie Pharmaceuticals Inc is the sale of 49,704 shares on December 23, 2014, which brought Clarus Lifesciences Ii, L.p. around $2 Million.
According to the SEC Form 4 filings, Clarus Lifesciences Ii, L.p. has made a total of 0 transactions in Astria Therapeutics Inc (ATXS) over the past 5 years. The most-recent trade in Astria Therapeutics Inc is the acquisition of 6,278 shares on June 30, 2015, which cost Clarus Lifesciences Ii, L.p. around $5 Million.
More details on Clarus Lifesciences Ii, L.p.'s insider transactions can be found in the Insider Trading History of Clarus Lifesciences Ii, L.p. table.Insider Trading History of Clarus Lifesciences Ii, L.p.
- 1
Clarus Lifesciences Ii, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Clarus Lifesciences Ii, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Clarus Lifesciences Ii, L.p. is 7.96%. GuruFocus also compares Clarus Lifesciences Ii, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Clarus Lifesciences Ii, L.p. within 3 months outperforms 3 times out of 5 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Clarus Lifesciences Ii, L.p.'s insider trading performs compared to the benchmark.
Performance of Clarus Lifesciences Ii, L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 1.54 | | | | | |
| Relative Return to S&P 500(%) | 2.61 | | | | | |
Clarus Lifesciences Ii, L.p. Ownership Network
Clarus Lifesciences Ii, L.p. Owned Company Details
What does NanoString Technologies Inc do?
Who are the key executives at NanoString Technologies Inc?
Clarus Lifesciences Ii, L.p. is the 10 percent owner of NanoString Technologies Inc. Other key executives at NanoString Technologies Inc include Chief Commercial Officer Jonathan Todd Garland , Chief Financial Officer K Thomas Bailey , and director & President and CEO R Bradley Gray .
NanoString Technologies Inc (NSTGQ) Insider Trades Summary
Over the past 18 months, Clarus Lifesciences Ii, L.p. made no insider transaction in NanoString Technologies Inc (NSTGQ). Other recent insider transactions involving NanoString Technologies Inc (NSTGQ) include a net purchase of 97,661 shares made by R Bradley Gray , a net purchase of 44,161 shares made by K Thomas Bailey , and a net purchase of 35,400 shares made by William Young .
In summary, during the past 3 months, insiders sold 0 shares of NanoString Technologies Inc (NSTGQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NanoString Technologies Inc (NSTGQ) were sold and 201,722 shares were bought by its insiders, resulting in a net purchase of 201,722 shares.
NanoString Technologies Inc (NSTGQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
NanoString Technologies Inc Insider Transactions
Clarus Lifesciences Ii, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Clarus Lifesciences Ii, L.p.. You might contact Clarus Lifesciences Ii, L.p. via mailing address: 101 Main Street, Suite 1210, Cambridge Ma 02142.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
